Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Puma Biotechnology's ebitda for the twelve months ending Jun 30, 2026 was $40.92M, down 28.6% year over year. For fiscal 2025 it was $48.24M, up 13.5% from the year before. The highest annual figure on record is $48.24M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.24M | +13.5% |
| FY2024 | Dec 31, 2024 | $42.49M | -3.8% |
| FY2023 | Dec 31, 2023 | $44.16M | +31.6% |
| FY2022 | Dec 31, 2022 | $33.56M | +166.5% |
| FY2021 | Dec 31, 2021 | $12.60M | – |
| FY2020 | Dec 31, 2020 | -$20.37M | – |
| FY2019 | Dec 31, 2019 | -$30.97M | – |
| FY2018 | Dec 31, 2018 | -$87.27M | – |
| FY2017 | Dec 31, 2017 | -$289.58M | – |
| FY2016 | Dec 31, 2016 | -$275.45M | – |
| FY2015 | Dec 31, 2015 | -$239.50M | – |
| FY2014 | Dec 31, 2014 | -$141.65M | – |
| FY2013 | Dec 31, 2013 | -$54.41M | – |
| FY2012 | Dec 31, 2012 | -$74.19M | – |
| FY2011 | Dec 31, 2011 | -$10.15M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.10M | +7.5% |
| Q1 FY2026 | Mar 31, 2026 | -$1.24M | -118.3% |
| Q4 FY2025 | Dec 31, 2025 | $19.76M | +21.9% |
| Q3 FY2025 | Sep 30, 2025 | $12.30M | -50.7% |
| Q2 FY2025 | Jun 30, 2025 | $9.40M | +1189.3% |
| Q1 FY2025 | Mar 31, 2025 | $6.78M | +1033.8% |
| Q4 FY2024 | Dec 31, 2024 | $16.21M | -8.4% |
| Q3 FY2024 | Sep 30, 2024 | $24.96M | +117.8% |
| Q2 FY2024 | Jun 30, 2024 | $729.00K | -90.6% |
| Q1 FY2024 | Mar 31, 2024 | $598.00K | -91.7% |
| Q4 FY2023 | Dec 31, 2023 | $17.69M | +41.8% |
| Q3 FY2023 | Sep 30, 2023 | $11.46M | +135.7% |
| Q2 FY2023 | Jun 30, 2023 | $7.77M | -46.5% |
| Q1 FY2023 | Mar 31, 2023 | $7.24M | +323.6% |
| Q4 FY2022 | Dec 31, 2022 | $12.47M | +27.1% |
| Q3 FY2022 | Sep 30, 2022 | $4.86M | – |
| Q2 FY2022 | Jun 30, 2022 | $14.52M | – |
| Q1 FY2022 | Mar 31, 2022 | $1.71M | -92.6% |
| Q4 FY2021 | Dec 31, 2021 | $9.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.51M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.70M | -246.3% |
| Q1 FY2021 | Mar 31, 2021 | $23.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.20M | – |
| Q2 FY2020 | Jun 30, 2020 | $9.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.34M | -202.9% |
| Q4 FY2019 | Dec 31, 2019 | -$6.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.51M | – |
| Q2 FY2019 | Jun 30, 2019 | -$23.68M | – |
| Q1 FY2019 | Mar 31, 2019 | $11.98M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.43M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.23M | – |
| Q2 FY2018 | Jun 30, 2018 | -$39.56M | – |
| Q1 FY2018 | Mar 31, 2018 | -$22.05M | – |
| Q4 FY2017 | Dec 31, 2017 | -$62.21M | – |
| Q3 FY2017 | Sep 30, 2017 | -$76.54M | – |
| Q2 FY2017 | Jun 30, 2017 | -$77.91M | – |
| Q1 FY2017 | Mar 31, 2017 | -$72.93M | – |
| Q4 FY2016 | Dec 31, 2016 | -$72.29M | – |
| Q3 FY2016 | Sep 30, 2016 | -$65.89M | – |
See a number that looks wrong?